XNK Therapeutics AB (“XNK”) today announced it will adopt the generic name evencaleucel for its lead candidate targeting multiple myeloma. Evencaleucel was recently recommended by the World Health Organization (WHO) as the International Nonproprietary Name (INN) for XNK’s leading drug candidate.
XNK Therapeutics AB (“XNK”) today announced the appointment of Dr. Anna-Karin Maltais as Chief Scientific Officer, effective October 17[th]. She will be a member of the company’s management team.
XNK Therapeutics AB (“XNK”) today announced the successful completion of the building phase of the company’s new GMP clean room facility.
XNK Therapeutics AB (“XNK”) today announced it is initiating a program targeting urothelial cancer, the most common form of bladder cancer. This is the first project where XNK’s proprietary technology platform of natural killer (NK) cell therapies is applied towards solid tumors. The company will collaborate with the Karolinska University Hospital in Solna, Sweden.
XNK Therapeutics AB (“XNK”) today announced that an abstract on the long-term follow-up of the Phase I/II clinical trial ACP-001 with its leading candidate drug was presented at European Hematology Association’s hybrid conference EHA2022, which is held in Vienna, Austria, on June 9[th]-12[th].
XNK Therapeutics AB (“XNK”) today announced that Ted Fjällman, Partner at Flerie Invest, has joined the company’s board of directors.
XNK Therapeutics AB (“XNK”) today announced that an abstract on the long-term follow-up of the Phase I/II clinical trial study ACP-001 with its leading candidate drug has been selected for a presentation at European Hematology Association’s hybrid conference EHA2022, which is held in Vienna, Austria, on June 9[th]-12[th].
XNK Therapeutics AB (“XNK”) today announced it has secured a private placement of SEK 132 million, to existing and new investors, led by Flerie Invest AB. The purpose of the issue is primarily to finance the company’s clinical development in multiple myeloma and other indications.
XNK Therapeutics AB (“XNK”) today announced that the first patient has been treated in a Phase II clinical study using XNK’s leading autologous natural killer (NK) cell-based candidate drug in combination with Sanofi’s anti-CD38 antibody Sarclisa (Isatuximab).
XNK Therapeutics AB’s CEO Johan Liwing will present at Redeye’s Regenerative Medicine/Cell Therapy event on February 23 at 09.50 CET. The presentation is broadcasted live and can be followed at: https://www.redeye.se/events/825130/redeye-theme-regenerative-medicine-cell-therapy
XNK Therapeutics AB (“XNK”) today announced that the first-in-human Phase I study ACP-001, performed at the Karolinska University Hospital in Huddinge, Sweden, has been published in Cell Reports Medicine. The study demonstrates that XNK’s autologous natural killer (NK) cell-based immunotherapy is feasible. Furthermore, it shows a good safety profile and promising efficacy data as consolidation treatment following autologous stem cell transplantation in patients newly diagnosed with multiple myeloma.
XNK Therapeutics AB (“XNK”) today announced the appointment of Dr. Gunilla Enblad, Professor of oncology at Uppsala University, and Dr. Rizwan Romee, Associate Professor of Medicine at Harvard Medical School, as scientific advisors. Together with the other advisors, they will play a key role in the future development of XNK’s proprietary technology platform of natural killer (NK) cell therapies within plasma cell disorders and hematological malignancies.
XNK Therapeutics AB (“XNK”) today announced it will perform a proof of concept study in acute myeloid leukemia (AML) using patient samples from The University of Texas MD Anderson Cancer Center.
XNK Therapeutics AB’s CEO, Johan Liwing, will present at the ABGSC Private Companies event on December 6. The presentation starts at 09:30CET and will be livestreamed via https://www.introduce.se.
XNK Therapeutics AB (“XNK”) today announced the strengthening of the company’s expertise by the appointment of Ola Landgren, M.D., Ph.D., Fredrik Schjesvold M.D., Ph.D. and Johan Lund M.D., Ph.D. These scientific advisors are key to the company’s plan to further expand the scope of its proprietary technology platform of natural killer (NK) cell therapies within plasma cell disorders and hematological malignancies.
September 29, 2021
XNK Therapeutics AB (“XNK”) today announced plans to further expand the scope of its proprietary technology platform of natural killer (NK) cell therapies outside of multiple myeloma to also include other cancer indications to broaden the pipeline. The company will begin the preclinical and commercial work to expand the pipeline and expects to announce a decision in Q1 2022.
XNK Therapeutics AB (“XNK”) today announced that Dr. David Berglund and Dr. Stephen Wooding are proposed to be appointed members of the Board of Directors. The decision will be taken at an extra…
XNK Therapeutics AB (“XNK”) today announced the appointment of Markus Thor as Chief Business Officer, effective September 6th. He will be member of the company’s management team. Mr….
After an intensive spring with preparation, planning, procurement, and design, the groundwork was laid for constructing a GMP facility that enables the aseptic production of ATMPs and clinical…
XNK Therapeutics AB (“XNK”) today announced that the first patient has been included in a Phase II clinical study to treat patients with Multiple myeloma using XNK’s leading autologous natural…
XNK Therapeutics AB (publ) today held its Annual General Meeting. The annual general meeting was held through advance voting (postal voting) in accordance with temporary legislation. The following…
XNK Therapeutics AB (“XNK”) today announced the appointment of Professor Michael Uhlin as Chief Scientific Officer, effective August 1st. He will be a member of the company’s…
XNK Therapeutics AB (“XNK”) today announced the appointment of Dr. Johan Aschan as Chief Medical Officer, effective July 1st. He will be member of the company’s management team. Dr….
XNK Therapeutics AB (“XNK” or the “Company”), a Swedish clinical stage immunotherapy company treating cancer by developing novel NK cell-based therapies, today announced the completion of a…
XNK Therapeutics AB (“XNK”) held an extraordinary general meeting on March 18, 2021, where the general meeting resolved to change the company category from private to public limited company. The…
XNK Therapeutics AB (“XNK”) today announced that it is entering into a joint Phase II clinical study to treat patients with multiple myeloma using XNK’s leading drug candidate in combination…
XNK Therapeutics AB (“XNK”) announces its collaboration agreement with Israel-based Cellect Biotechnology (“Cellect”) to develop the next generation version of XNK’s innovative technology…
XNK Therapeutics AB (“XNK”) today announced it has received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for its leading investigational drug candidate in the…
The extraordinary general meeting in XNK Therapeutics AB (“the Company”) was held on October 14, 2020, where the general meeting resolved in accordance with submitted proposals. The following…
XNK Therapeutics AB (“XNK”) today announced the appointment of Dr. Stephan Meinke as Head of R&D Dr. Meinke received his doctorate degree in 2010 from the University of Heidelberg, Germany,…
Today results from the first-in-human study ACP-001 was made public at the 2020 EHA meeting. Key findings from the study: Overall survival (OS) 100% after a median follow-up time of 60 months…
XNK Therapeutics AB (“XNK”) today announced the appointment of Hans Ericson as Chief Financial Officer Hans Ericson is a senior finance professional with more than 20 years’ experience in…
XNK Therapeutics AB (“XNK”) today announced its appointment of Johan Liwing as CEO of the company and prepares for the next phase of development of its technology platform and leading drug…
XNK Therapeutics AB (“XNK”) today announced it joined Sweden’s Innovation Agency’s NextGenNK competence center for the development of next-generation natural killer (NK) cell-based cancer…
XNK Therapeutics AB (“XNK”) today announced its European patent for the process of expanding NK cells has been validated in 18 countries across the region. The patent covers XNK’s production…
XNK Therapeutics AB (“XNK”) today announced that Japan has granted the company a patent for its process of expanding NK cells The patent covers XNK’s production methods for expansion and…
XNK Therapeutics AB (“XNK”) today announced it has received a European patent for the process of expanding NK cells. The patent covers XNK’s production methods for large scale expansion and…
XNK Therapeutics AB (“XNK”) today announced that Vinnova, a Swedish government-sponsored innovation agency, has granted XNK SEK1 million to upscale production of CellProtect. “We are extremely…
XNK Therapeutics AB (“XNK”) today announced that Korea has granted the company a patent for its process of expanding NK cells. The patent covers XNK’s production methods for expansion and…
XNK Therapeutics AB (“XNK”) today announced it has become a partner in Swelife’s health economics project on Advanced Therapy Medicinal Products (ATMP). The partnership allows the company to…
XNK Therapeutics AB (“XNK”) today announced it strengthened its organization by appointing Agneta Edberg to the board of directors. Agneta Edberg has over 25 years’ experience from leading…
XNK Therapeutics AB (“XNK”) today announced that the Swedish government-sponsored innovation agency Vinnova has granted XNK SEK1 million to partner in The Competence Centre for Advanced…
XNK Therapeutics AB (“XNK”) announced today it received a patent from the US for its method of treating multiple myeloma with expanded NK cells. “Being granted this patent in the US is an…
